Notice of allowance has been granted to member patents of this family in the US, Japan, India, China, Korea, Mexico, Israel and Australia.
BL-1020 is a novel, first in class, oral therapeutic for schizophrenia, and according to pre-clinical and clinical studies BL-1020 is effective at treating schizophrenia symptoms and has a good safety profile.
BioLineRx CEO Kinneret Savitsky said the company is extremely pleased at receiving approval for the European Patent covering BL-1020 which joins the broad protection the company has already received in other territories, securing a broad basis for its future commercial operations.
"We believe this represents significant further progress in the development and commercialization of BL-1020," Savitsky added.
"BL-1020 has previously demonstrated improved cognitive function in schizophrenia patients, and we are currently conducting the CLARITY clinical trial, which has validation of BL-1020’s cognition enhancement as its primary objective. We expect to obtain results during mid-2013."